ADC Therapeutics
ADCT

$3.63

4.97%

Market Cap: 349M

About: ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.

Employees: 274

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,702 funds

0

Analysts bullish %

of 7 analysts

0

News positive %

of 3 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

196% more call options, than puts

Call options by funds: $902K | Put options by funds: $305K

176% more capital invested

Capital invested by funds: $56.4M [Q4 2023] → $156M (+$99.4M) [Q1 2024]

50% more funds holding in top 10

Funds holding in top 10: 2 [Q4 2023] → 3 (+1) [Q1 2024]

3.89% more ownership

Funds ownership: 38.13% [Q4 2023] → 42.03% (+3.89%) [Q1 2024]

0% more funds holding

Funds holding: 37 [Q4 2023] → 37 (+0) [Q1 2024]

0% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 12

22% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 9

See Fund Rankings

Research analyst outlook

7 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target

$8

120%

upside

Avg. target

$8.86

144%

upside

High target

$11

203%

upside

7 analyst ratings

7 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Robert Burns	120%upside $8	Buy Maintained	7 May 2024
HC Wainwright & Co. Robert Burns	148%upside $9	Buy Reiterated	15 Apr 2024
Guggenheim Michael Schmidt	203%upside $11	Buy Initiated	28 Mar 2024
RBC Capital Gregory Renza	120%upside $8	Outperform Reiterated	14 Mar 2024
HC Wainwright & Co. Robert Burns	148%upside $9	Buy Reiterated	6 Mar 2024

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about ADCT published over the past 30 days

7 Growth Stocks to Buy for Under $5 for Massive Gains

With growth stocks under $5, the focal point is rather obvious: putting woodwork on the ball as aggressively as possible. Of course, swinging for the fences comes with significant risks.

7 Growth Stocks to Buy for Under $5 for Massive Gains

Myricx Bio Announces £90m ($114m) Series A Financing to Advance its Novel NMTi-ADC Therapeutics into Clinical Development

LONDON, July 08, 2024 (GLOBE NEWSWIRE) -- Myricx Bio (‘Myricx'), a UK biotech company focusing on the discovery and development of a completely novel class of payloads for antibody-drug conjugates (ADCs), today announced the closing of its series A financing raising £90m ($114m). The round was co-led by new leading life science investors Novo Holdings and Abingworth. Additional new investors British Patient Capital (a wholly owned commercial subsidiary of British Business Bank plc, the UK government's economic development bank), Cancer Research Horizons and Eli Lilly and Company also participated alongside founding investors Brandon Capital and Sofinnova Partners.

Myricx Bio Announces £90m ($114m) Series A Financing to Advance its Novel NMTi-ADC Therapeutics into Clinical Development

ADC Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes

LAUSANNE, Switzerland, June 27, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that the Company is set to join the Russell 2000® Index and the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024.

ADC Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes

Stocks to Buy: 3 Biotech Bargains Delivering Breakthroughs on a Budget

Fundamentally, biotech stocks to buy operate on a clear and unavoidable narrative: wealth means nothing without health. You hear various stories about extremely wealthy tycoons throwing all kinds of money, not just for lifesaving procedures but in more superficial efforts such as maintaining youth and vitality.

Stocks to Buy: 3 Biotech Bargains Delivering Breakthroughs on a Budget

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

LAUSANNE, Switzerland, June 03, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that the Company has made grants of options to purchase an aggregate of 109,800 of the Company's common shares to three new employees on June 3, 2024 (each, a “Grant”). The Grants were offered as material inducement to the employees' employment. The grants were approved by the Compensation Committee of the Company's Board of Directors pursuant to the Company's Inducement Plan to motivate and reward the recipients to perform at the highest levels and contribute significantly to the success of the Company. The Grants were made in reliance on the employment inducement exemption under the NYSE's Listed Company Manual Rule 303A.08. The Company is issuing this press release pursuant to Rule 303A.08. The Grants shall vest and become exercisable 25% on the first anniversary of the grant date, and 1/48th of the aggregate number of shares subject to the award on each monthly anniversary of the grant date thereafter, such that the entire award will be vested as of the fourth anniversary of the grant date, subject to continued employment with the Company.

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

ADC Therapeutics to Participate in the Jefferies Global Healthcare Conference

LAUSANNE, Switzerland, May 30, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will present a company overview at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 11:30 a.m. ET.

ADC Therapeutics to Participate in the Jefferies Global Healthcare Conference

ADC Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

LAUSANNE, Switzerland, May 15, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ on Monday, May 20, 2024 at 2:00 p.m. ET.

ADC Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

ADC Therapeutics to Participate in 2024 RBC Capital Markets Global Healthcare Conference

LAUSANNE, Switzerland, May 09, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference on Tuesday, May 14, 2024, at 1:35 p.m. ET.

ADC Therapeutics to Participate in 2024 RBC Capital Markets Global Healthcare Conference

ADC Therapeutics SA (ADCT) Q1 2024 Earnings Call Transcript

ADC Therapeutics SA (NYSE:ADCT ) Q1 2024 Earnings Conference Call May 6, 2024 8:30 AM ET Company Participants Nicole Preiss-Riley - Executive Director, Head of Communications Ameet Mallik - CEO Kristen Herrington-Smith - Chief Commercial Officer Mohamed Zaki - CMO Patrick van Berkel - Chief Scientific Officer Jose Carmona - CFO Conference Call Participants Yun Zhong - Jefferies Michael Schmidt - Guggenheim Securities Unidentified Analyst - RBC Capital Markets Brian Cheng - J.P. Morgan Chase Operator Good day and thank you for standing by.

ADC Therapeutics SA (ADCT) Q1 2024 Earnings Call Transcript

Zacks Investment Research

ADC Therapeutics SA (ADCT) Reports Q1 Loss, Misses Revenue Estimates

ADC Therapeutics SA (ADCT) came out with a quarterly loss of $0.56 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.74 per share a year ago.

ADC Therapeutics SA (ADCT) Reports Q1 Loss, Misses Revenue Estimates

See News Rankings